Supplementary Figure S10 from JAB-3312, a Potent Allosteric SHP2 Inhibitor That Enhances the Efficacy of RTK/RAS/MAPK and PD-1 Blockade Therapies

Supplementary Figure S10. CT images of representative clinical cases over the course of treatment. A. Images of the target legions (nodules in the lower lobe of the right lung and the upper lobe of the left lung) over time in a patient with KRAS G12C mutant NSCLC who received JAB-3312 and glecirasib combination therapy. B. Images of the target legion (nodule in the upper lobe of the left lung) over time in a patient with KRAS G12C mutant NSCLC who received JAB-3312 and glecirasib combination therapy. C. Images of the target legion (nodule in the upper lobe of the left lung) over time in a patient with KRAS G12C mutant NSCLC who received JAB-3312 and glecirasib combination therapy. D. Images of the target legion (intra-abdominal nodule) over time in a patient with KRAS G12V mutant ovarian serous carcinoma who received JAB-3312 and binimetinib combination therapy. E. Images of the target legion (left abdominal wall nodule) over time in a patient with ESCC who received JAB-3312 and pembrolizumab combination therapy.